LLY: Ilya Yuffa sold 1,250 shares at $627.01 under 10b5-1 plan

Q: What transaction did Ilya Yuffa report on the Form 4 for LLY?

The Form 4 reports a sale of 1,250 shares of Eli Lilly common stock on 08/11/2025 at a reported price of $627.01 per share.

Q: How many Eli Lilly shares did Yuffa own after the reported sale?

The Form 4 lists 26,259.971 shares beneficially owned following the reported transaction, held in a direct ownership form.

Q: What is Ilya Yuffa's relationship to Eli Lilly as shown on the form?

The reporting person is identified as an Officer with the title EVP & Pres, LLY USA & Global Capab .

[Form 4] Eli Lilly & Co. Insider Trading Activity

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Ilya Yuffa, listed as EVP & President, LLY USA & Global Capab and an officer of Eli Lilly & Co., reported a sale of 1,250 shares of Eli Lilly common stock on 08/11/2025 at a reported price of $627.01 per share.

The Form 4 shows the sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. Following the reported transaction the form lists 26,259.971 shares beneficially owned by the reporting person in a direct ownership form. No derivative transactions are reported in Table II.

Positive

Transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025, as stated on the Form 4.

Negative

None.

Insights

TL;DR: Routine pre-planned officer sale; limited immediate market impact from disclosed details.

The filing documents a single non-derivative disposition of 1,250 common shares at $627.01 on 08/11/2025. The transaction was executed under a Rule 10b5-1 plan adopted on February 12, 2025, which indicates the sale followed a pre-established schedule rather than an ad-hoc trade. The report also shows 26,259.971 shares beneficially owned following the trade. There are no derivative transactions disclosed, and the filing contains no additional financial metrics or material corporate events.

TL;DR: Use of a 10b5-1 plan signals compliance with insider trading protocols; disclosure is straightforward.

The Form 4 explicitly states the sale was made pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025, reflecting a pre-authorized framework intended to provide an affirmative defense under applicable rules. The reporting person is identified as an officer and the transaction was a direct sale of 1,250 shares at $627.01. No derivatives or other compensatory transactions are noted, and the filing does not disclose any other governance or control changes.

08/12/2025 - 04:16 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yuffa Ilya

(Last)

(First)

(Middle)

LILLY CORPORATE CENTER

(Street)

INDIANAPOLIS

46285

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP&Pres, LLY USA&Global Capab

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/11/2025		S⁽¹⁾		1,250	D	$627.01	26,259.971	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 12, 2025.

Remarks:

	/s/ Jonathan Groff for Ilya Yuffa, pursuant to authorization on file	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What transaction did Ilya Yuffa report on the Form 4 for LLY?

The Form 4 reports a sale of 1,250 shares of Eli Lilly common stock on 08/11/2025 at a reported price of $627.01 per share.

Was the sale by Ilya Yuffa part of a pre-existing trading plan?

Yes. The filing states the transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

How many Eli Lilly shares did Yuffa own after the reported sale?

The Form 4 lists 26,259.971 shares beneficially owned following the reported transaction, held in a direct ownership form.

What is Ilya Yuffa's relationship to Eli Lilly as shown on the form?

The reporting person is identified as an Officer with the title EVP & Pres, LLY USA & Global Capab.

Does the Form 4 report any derivative transactions for Ilya Yuffa?

No. Table II shows no derivative securities acquired, disposed of, or beneficially owned; only a non-derivative common stock sale is reported in Table I.

AG真人官方

[Form 4] Eli Lilly & Co. Insider Trading Activity

Insights

FAQ

What transaction did Ilya Yuffa report on the Form 4 for LLY?

Was the sale by Ilya Yuffa part of a pre-existing trading plan?

How many Eli Lilly shares did Yuffa own after the reported sale?

What is Ilya Yuffa's relationship to Eli Lilly as shown on the form?

Does the Form 4 report any derivative transactions for Ilya Yuffa?

NYSE:LLY

LLY Rankings

LLY Latest News

LLY Latest SEC Filings

LLY Stock Data

AG真人官方

Trending News

[Form 4] Eli Lilly & Co. Insider Trading Activity

Insights

Financial Analyst neutral

Corporate Governance Expert neutral

FAQ

What transaction did Ilya Yuffa report on the Form 4 for LLY?

Was the sale by Ilya Yuffa part of a pre-existing trading plan?

How many Eli Lilly shares did Yuffa own after the reported sale?

What is Ilya Yuffa's relationship to Eli Lilly as shown on the form?

Does the Form 4 report any derivative transactions for Ilya Yuffa?

NYSE:LLY

LLY Rankings

LLY Latest News

LLY Latest SEC Filings

LLY Stock Data